Somewhat Positive Press Coverage Somewhat Unlikely to Affect Astrazeneca PLC (AZN) Share Price
News articles about Astrazeneca PLC (NYSE:AZN) have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Astrazeneca PLC earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8314760410778 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- AstraZeneca plc’s (AZN) “Hold” Rating Reaffirmed at Shore Capital – Newburgh Gazette (newburghgazette.com)
- Astrazeneca PLC (AZN) Upgraded at Investec (americanbankingnews.com)
- Astrazeneca PLC (AZN) Ex-Dividend Date Scheduled for August 09, 2017 – Nasdaq (nasdaq.com)
- Astrazeneca PLC (NYSE:AZN) Stock Rating Lowered by BidaskClub (americanbankingnews.com)
- [$$] AstraZeneca is beginning to look a lot like Tesco (finance.yahoo.com)
Shares of Astrazeneca PLC (NYSE:AZN) traded up 0.55% during mid-day trading on Wednesday, reaching $29.47. The company’s stock had a trading volume of 4,132,105 shares. Astrazeneca PLC has a one year low of $25.55 and a one year high of $35.60. The firm has a market cap of $74.62 billion, a PE ratio of 19.33 and a beta of 0.74. The firm’s 50 day moving average is $33.57 and its 200 day moving average is $31.37.
Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business’s quarterly revenue was down 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.83 earnings per share. On average, equities analysts anticipate that Astrazeneca PLC will post $1.85 earnings per share for the current fiscal year.
The firm also recently declared a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. Astrazeneca PLC’s payout ratio is presently 44.92%.
A number of research analysts have commented on AZN shares. Zacks Investment Research lowered Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Cowen and Company reaffirmed a “hold” rating and set a $34.00 price target on shares of Astrazeneca PLC in a research report on Friday, July 28th. Credit Suisse Group raised Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research report on Friday, May 12th. Finally, Leerink Swann lowered Astrazeneca PLC from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $36.00 to $31.00 in a research report on Thursday, July 27th. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $33.39.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.